Roger Hunter

Biography

A successful senior leader with almost 30 years of commercial and development experience in large pharmaceutical companies, startup biotech companies and CROs, Roger Hunter is Chiltern’s executive vice president of scientific affairs & strategic development. In this role, he is responsible for providing strategic consultation to clients around their development plans, and for operational oversight of studies by providing critical scientific advice and developing appropriate governance structures to manage strategic relationships. Before joining Chiltern, Hunter was president at D&R Biopharma Consulting LLC. He was also vice president of operations at Cardiokine, where he oversaw clinical development, regulatory affairs, CMC and project management activities for the development of lixivaptan, a vasopressin receptor antagonist in development for hyponatremia and congestive heart failure, and was involved all the way through to the product’s completed and filed NDA. Hunter earned his bachelor’s degree from Aberdeen University in Scotland and a diploma from Chartered Institute of Marketing, Ealing College in London. Hunter is based near King of Prussia, Pennsylvania. 

Research Interest

Roger Hunter is an expert in small-molecule drug development and in the use of genetic model systems in drug discovery and has deep experience in translational research focused on drug development and the use of genetic markers to predict drug sensitivity.